AMGN compared with INBX: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

INBXInhibrx Biosciences, Inc.

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

INBXInhibrx Biosciences, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

AMGNAmgen Inc

463.41▼−0.44%

Mkt cap$251.6BRevenue$10.1BQ2 FY26Revenue$36.8BFY25

INBXInhibrx Biosciences, Inc.

81.36▲+12.75%

Regular sessionNov 3 '26

Mkt cap$1.1BRevenue$1MQ2 FY25Revenue—

Compare

Regular sessionNov 3 '26

AMGNAmgen Inc

INBXInhibrx Biosciences, Inc.

463.41▼−0.44%

Price

81.36▲+12.75%

$251.6B

Mkt cap

$1.1B

Q2 FY26$10.1B

Revenue

$1MQ2 FY25

FY25$36.8B

Revenue

—

AMGN463.41▼−0.44%vsINBX81.36▲+12.75%Regular sessionNov 3 '26

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

INBX: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

8 more · AMGN chain ›

Shared 0

No shared counterparties.

Only INBX 4

REGNRegeneron Pharmaceuticalscustomer

SNYSanoficustomer

—Scitheraunlistedcustomer

—Art Acquisition Sub

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

unlistedcustomer

Price

rebased to 0%

AMGN, solidINBX, dashed